hat
Viris epatit B te (HBV) reyaktivasyon te rapòte nan HCV / HBV pasyan coinfected granmoun ki te sibi oswa te ranpli tretman ak HCV antiviral dirèk-aji, epi ki pa t ap resevwa HBV antiviral terapi. HBV reyaktivasyon nan pasyan trete ak dirèk-aji medikaman antiviral ka rezilta nan pwoblèm fwa grav oswa lanmò nan kèk pasyan yo. pwofesyonèl swen sante ta dwe ekran tout pasyan pou bay prèv nan enfeksyon HBV aktyèl oswa anvan anvan yo kòmanse tretman ak Vosevi.
eng
Hepatitis B virus (HBV) reactivation has been reported in HCV/HBV coinfected adult patients who were undergoing or had completed treatment with HCV direct-acting antivirals, and who were not receiving HBV antiviral therapy. HBV reactivation in patients treated with direct-acting antiviral medicines can result in serious liver problems or death in some patients. Health care professionals should screen all patients for evidence of current or prior HBV infection before starting treatment with Vosevi.